A new antibody that blocks eNAMPT to reduce lung injury from hospital- and ventilator-associated pneumonia
Official title: A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia
Funded at University of Florida · NIH-11366090 · Data updated 2026-11-12
A new antibody treatment is being tested to lessen lung damage from hospital- and ventilator-associated pneumonia and to help prevent the spread of antibiotic resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | June 24, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $861,088 |
| NIH project number | 1R01AI189492-01A1 |
| Project ID | NIH-11366090 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with hospital-acquired or ventilator-associated pneumonia and/or acute respiratory distress syndrome who meet trial criteria and are treated in ICU settings.
✕Less likely to help
Patients without HABP/VABP or those not meeting inclusion criteria may not experience benefit from this specific therapy.
What this research studies
This project tests a novel antibody called ALT-100 that targets eNAMPT, a molecule involved in excessive lung inflammation. By modulating the immune response, the study aims to reduce severe lung injury and improve lung function in patients with HABP/VABP. The research builds on preclinical and early human data to define three specific goals around safety, lung protection, and impact on infection-related pathology. If successful, it could lead to a new immunomodulatory therapy for serious pneumonia in ICU patients.
Why it matters
Potential benefit: If successful, the treatment could lessen lung damage and improve outcomes for patients with HABP/VABP and ARDS, potentially reducing mortality and duration of illness.
How similar studies have gone: Preclinical data and limited Phase 2A signals in related ARDS/VILI/sepsis work suggest potential benefit, though full efficacy in HABP/VABP remains to be proven in larger trials.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Garcia, Joe G. N. — University of Florida
- Study coordinator: Garcia, Joe G. N.
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Endothelial inflammation memory after sepsis and pneumonia
A scientist is studying how blood vessel cells “remember” sepsis and why survivors get worse when they catch pneumonia, with the goal of finding better ways to reduce organ damage.
-
Bacterial Biofilm Therapy with a Human Antibody to Help Antibiotics Work Better
A human antibody drug is being studied to disrupt bacterial biofilms and help standard antibiotics clear infections, especially around implants and catheters, in adults.
-
A tissue slice model to test treatments for Pneumocystis pneumonia in people with HIV/AIDS
Researchers are creating a lung-slice model to study Pneumocystis jirovecii pneumonia and test potential treatments using tissue from infected, immunosuppressed mice to better predict what might help people with HIV/AIDS.
-
Measuring respiratory and gut bacteria to predict pneumonia treatment failure
A project to understand how bacterial load in the lungs and gut changes during and after antibiotics for hospital-acquired and ventilator-associated pneumonia, with the goal of predicting which patients might fail treatment.
-
Better tests and treatments for Pneumocystis (PCP) pneumonia
Developing more accurate tests and safer treatment options for people with weakened immune systems who get Pneumocystis pneumonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.